SG11201809658UA - Tablet-in-tablet pharmaceutical composition comprising cyclophosphamide and capecitabine - Google Patents
Tablet-in-tablet pharmaceutical composition comprising cyclophosphamide and capecitabineInfo
- Publication number
- SG11201809658UA SG11201809658UA SG11201809658UA SG11201809658UA SG11201809658UA SG 11201809658U A SG11201809658U A SG 11201809658UA SG 11201809658U A SG11201809658U A SG 11201809658UA SG 11201809658U A SG11201809658U A SG 11201809658UA SG 11201809658U A SG11201809658U A SG 11201809658UA
- Authority
- SG
- Singapore
- Prior art keywords
- gujarat
- floor
- gurudwara
- bodakdev
- ahmedabad
- Prior art date
Links
- GAGWJHPBXLXJQN-UORFTKCHSA-N Capecitabine Chemical compound C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](C)O1 GAGWJHPBXLXJQN-UORFTKCHSA-N 0.000 title abstract 3
- GAGWJHPBXLXJQN-UHFFFAOYSA-N Capecitabine Natural products C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1C1C(O)C(O)C(C)O1 GAGWJHPBXLXJQN-UHFFFAOYSA-N 0.000 title abstract 3
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 title abstract 3
- 229960004117 capecitabine Drugs 0.000 title abstract 3
- 229960004397 cyclophosphamide Drugs 0.000 title abstract 3
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 3
- 239000003814 drug Substances 0.000 abstract 8
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 229940000425 combination drug Drugs 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2893—Tablet coating processes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property 11111111111111111111111111111111111111101111111111111H11111011111111111110111111 Organization International Bureau (10) International Publication Number (43) International Publication Date ......0\" WO 2017/191553 Al 09 November 2017 (09.11.2017) W I P0 I P C T (51) International Patent Classification: (84) Designated States (unless otherwise indicated, for every A61K 31/7072 (2006.01) kind of regional protection available): ARIPO (BW, GH, (21) International Application Number: GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, PCT/1B2017/052534 UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, (22) International Filing Date: EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, 02 May 2017 (02.05.2017) MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, (25) Filing Language: English KM, ML, MR, NE, SN, TD, TG). (26) Publication Language: English Declarations under Rule 4.17: (30) Priority Data: — as to applicant's entitlement to apply for and be granted a 201621015342 03 May 2016 (03.05.2016) IN patent (Rule 4.1 7(ii)) (71) Applicant: INTAS PHARMACEUTICALS LTD. — as to the applicant's entitlement to claim the priority of the [IN/IN]; Intas Pharmaceuticals Ltd., 2nd Floor, Chinubhai earlier application (Rule 4.1 7(iii)) Centre, Ashram Road, Ahmedabad— 380009, Gujarat (IN). Published: (72) Inventors: PATEL, Priyank; Intas Pharmaceuticals Ltd — with international search report (Art. 21(3)) - Astron Division, 2nd & 10th Floor, Premier House — 1, Opp. Gurudwara, S. G. Highway, Bodakdev, Ahmedabad — 380054, Gujarat (IN). PATEL, Mayur; Intas Pharma- ceuticals Ltd - Astron Division, 2nd & 10th Floor, Premier — = House — 1, Opp. Gurudwara, S. G. Highway, Bodakdev, Ahmedabad— 380054, Gujarat (IN). PATEL, Mahendra; = _ Intas Pharmaceuticals Ltd - Astron Division, 2nd & 10th Floor, Premier House — 1, Opp. Gurudwara, S. G. Highway, Bodakdev, Ahmedabad — 380054, Gujarat (IN). SINGH, = Balvir; Intas Pharmaceuticals Ltd - Astron Division, 2nd & 10th Floor, Premier House — 1, Opp. Gurudwara, S. G. = _ Highway, Bodakdev, Ahmedabad — 380054, Gujarat (IN). SEHGAL, Ashish; Intas pharmaceuticals Limited - Astron — Division, 2nd & 10th Floor, Premier House-1, Bodakdev, _ Opp. Gurudwara, Sarkhej — Gandhinagar Highway, Ahmed- _ abad = 380054. Gujarat (IN). (74) Agent: PATHAK, Alpesh; Intas Pharmaceuticals Ltd - Astron Division, 2nd & 10th Floor, Premier House 1, — = Opp. Gurudwara, S. G. Highway, Bodakdev, Ahmedabad — = = 380054, Gujarat (IN). = (81) Designated States (unless otherwise indicated, for every kind of national available): AE, AG, AL, AM, = protection — AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, = — CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, _ = DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, _ MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, 1-1 PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, M TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. in in Il 0\ Il N (54) Title: TABLET-IN-TABLET PHARMACEUTICAL COMPOSITION COMPRISING CYCLOPHOSPHAMIDE AND 1-1 CAPECITABINE 0 ei (57) : The present invention relates to a stable tablet-in-tablet pharmaceutical composition comprising fixed dose combinations C of cyclophosphamide and capecitabine and one or more pharmaceutically acceptable excipient, process for the preparation thereof, and their use in treating cancer diseases.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN201621015342 | 2016-05-03 | ||
| PCT/IB2017/052534 WO2017191553A1 (en) | 2016-05-03 | 2017-05-02 | Tablet-in-tablet pharmaceutical composition comprising cyclophosphamide and capecitabine |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201809658UA true SG11201809658UA (en) | 2018-11-29 |
Family
ID=60202819
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201809658UA SG11201809658UA (en) | 2016-05-03 | 2017-05-02 | Tablet-in-tablet pharmaceutical composition comprising cyclophosphamide and capecitabine |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20190142755A1 (en) |
| EP (1) | EP3452054A4 (en) |
| CN (1) | CN109195609A (en) |
| AU (1) | AU2017260751A1 (en) |
| BR (1) | BR112018072583A2 (en) |
| CA (1) | CA3022799A1 (en) |
| MX (1) | MX2018013428A (en) |
| SG (1) | SG11201809658UA (en) |
| WO (1) | WO2017191553A1 (en) |
| ZA (1) | ZA201808051B (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021245519A1 (en) * | 2020-06-01 | 2021-12-09 | Shilpa Medicare Limited | Fast dispersible pharmaceutical composition comprising capecitabine |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5047246A (en) * | 1988-09-09 | 1991-09-10 | Bristol-Myers Company | Direct compression cyclophosphamide tablet |
| CA2925960A1 (en) * | 2013-09-30 | 2015-04-02 | Intas Pharmaceuticals Limited | Pharmaceutical composition comprising capecitabine and cyclophosphamide |
| AR100820A1 (en) * | 2014-06-12 | 2016-11-02 | Sanofi-Synthelabo (India) Ltd | FORMULATIONS OF COMPRESSED BI-LAYER OF CYCLOFOSPHAMIDE AND CAPECITABINE AND HIGHLY FRACTIONED METRONOMIC ADMINISTRATION OF THE SAME |
| US10016447B2 (en) * | 2014-09-26 | 2018-07-10 | Intas Pharmaceuticals Ltd. | Pharmaceutical composition having improved content uniformity |
| CN106822155B (en) * | 2016-12-29 | 2019-10-11 | 东北制药集团股份有限公司 | Piece and preparation method thereof in three Compound Tablet of efavirenz, Lamivudine and tenofovir disoproxil fumarate |
-
2017
- 2017-05-02 BR BR112018072583-8A patent/BR112018072583A2/en not_active Application Discontinuation
- 2017-05-02 AU AU2017260751A patent/AU2017260751A1/en not_active Abandoned
- 2017-05-02 SG SG11201809658UA patent/SG11201809658UA/en unknown
- 2017-05-02 US US16/099,088 patent/US20190142755A1/en not_active Abandoned
- 2017-05-02 EP EP17792578.1A patent/EP3452054A4/en not_active Withdrawn
- 2017-05-02 CA CA3022799A patent/CA3022799A1/en not_active Abandoned
- 2017-05-02 MX MX2018013428A patent/MX2018013428A/en unknown
- 2017-05-02 CN CN201780032891.0A patent/CN109195609A/en active Pending
- 2017-05-02 WO PCT/IB2017/052534 patent/WO2017191553A1/en not_active Ceased
-
2018
- 2018-11-28 ZA ZA2018/08051A patent/ZA201808051B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| BR112018072583A2 (en) | 2019-02-19 |
| EP3452054A1 (en) | 2019-03-13 |
| WO2017191553A1 (en) | 2017-11-09 |
| MX2018013428A (en) | 2019-10-07 |
| ZA201808051B (en) | 2020-05-27 |
| CN109195609A (en) | 2019-01-11 |
| EP3452054A4 (en) | 2019-12-25 |
| CA3022799A1 (en) | 2017-11-09 |
| US20190142755A1 (en) | 2019-05-16 |
| AU2017260751A1 (en) | 2018-11-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201811470PA (en) | Pyrazolopyrimidine derivatives as kinase inhibitor | |
| SG11201809299QA (en) | Formulations of an lsd1 inhibitor | |
| SG11201811549UA (en) | Boronic acid derivatives and therapeutic uses thereof | |
| SG11201809751XA (en) | Egfr inhibitor compounds | |
| SG11201901063SA (en) | Therapeutic agents for neurodegenerative diseases | |
| SG11201810423XA (en) | Pd-1 / pd-l1 inhibitors for cancer treatment | |
| SG11201810628XA (en) | Nasal pharmaceutical compositions with a porous excipient | |
| SG11201900633XA (en) | Piperidine cxcr7 receptor modulators | |
| SG11201901996UA (en) | Formulations of ( r)-2-amino-3-phenylpropyl carbamate | |
| SG11201807784SA (en) | 3-desoxy derivative and pharmaceutical compositions thereof | |
| SG11201908786VA (en) | Substituted indoline derivatives as dengue viral replication inhibitors | |
| SG11201901534VA (en) | Combination therapy with controlled-release cnp agonists | |
| SG11201810280YA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| SG11201808237UA (en) | Substituted indole compound derivatives as dengue viral replication inhibitors | |
| SG11201900558RA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| SG11201908465QA (en) | Substituted indoline derivatives as dengue viral replication inhibitors | |
| SG11201903076QA (en) | Carbamoyl phenylalaninol compounds and uses therof | |
| SG11201908691PA (en) | Compounds and methods for the treatment of parasitic diseases | |
| SG11201808676RA (en) | Methods of treating pediatric cancers | |
| SG11201909825VA (en) | Hsp90 inhibitor oral formulations and related methods | |
| SG11201900551WA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| SG11201903061YA (en) | Combination treatments comprising administration of imidazopyrazinones | |
| SG11201908660RA (en) | N-substituted indole derivatives | |
| SG11201900546UA (en) | Spiro-lactam and bis-spiro-lactam nmda receptor modulators and uses thereof | |
| SG11201900361RA (en) | Methods of treating prostate cancer |